CICC analyst maintained a Buy rating on Ascentage Pharma Group International yesterday and set a price target of HK$71.20. Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisionsDiscover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor PicksAscentage Pharma Group International has an analyst consensus of Moderate Buy, with a price target consensus of HK$71.20. Based on Ascentage Pharma Group International’s latest earnings release for the quarter ending June 30, the company reported a quarterly revenue of HK$233.7 million and a GAAP net loss of HK$590.77 million. In comparison, last year the company earned a revenue of HK$823.75 million and had a net profit of HK$163 million

Source: International New York Times April 06, 2026 06:03 UTC